Recurrence of benign paroxysmal positional vertigo: experience in 3042 patients

Roberto Teggi1, Riccardo Guidetti2, Omar Gatti1

  • 1Division of Otolaryngology, IRCCS San Raffaele Scientific Institute, Milan, Italy.

Abstract

Insights

Anti-thyroid antibodies may predict recurrent benign paroxysmal positional vertigo (BPPV) in individuals aged 40-60. This finding suggests a link between autoimmune factors and BPPV recurrence, aiding in understanding and managing this inner ear disorder.

Area of Science:

  • Neurology
  • Immunology
  • Otolaryngology

Background:

  • Benign paroxysmal positional vertigo (BPPV) frequently recurs.
  • Vascular disorders, migraine, and autoimmune conditions are suspected contributing factors to BPPV relapses.

Purpose of the Study:

  • To investigate the association between vascular disorders, migraine, and anti-thyroid antibodies with BPPV recurrences.
  • To identify predictive factors for BPPV relapse.

Main Methods:

  • Retrospective analysis of 3042 BPPV patients without other vertigo history.
  • Data collected included history of central nervous system vascular disorders, heart disease, migraine, head trauma, and anti-thyroid antibodies.

Main Results:

  • Recurrences were observed in 67.3% of patients within two years.
  • Central nervous system vascular disorders, anti-thyroid antibodies, head trauma, and migraine were associated with recurrences.
  • Anti-thyroid antibodies were particularly predictive of recurrence in patients experiencing their first BPPV episode between ages 40 and 60.

Conclusions:

  • Findings support the role of anti-thyroid autoantibodies in BPPV recurrences.
  • This association is most notable in patients with initial BPPV onset between 40 and 60 years old.